Cargando…
Valproate use in women aged 15–44 years: an observational study in general practice
BACKGROUND: Valproate is a known teratogen. In April 2018, the Medicines and Healthcare products Regulatory Agency (MHRA) restricted its use in women and banned use in pregnancy, except for epilepsy with no other effective treatment. To date, there is limited information on valproate prescribing wit...
Autores principales: | Beardsley, Samantha J, Dostal, Isabel, Cole, James, Gutierrez, Ana, Robson, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal College of General Practitioners
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170604/ https://www.ncbi.nlm.nih.gov/pubmed/33619016 http://dx.doi.org/10.3399/BJGPO.2020.0104 |
Ejemplares similares
-
An Audit of Risk Acknowledgment of Valproate Use in Women (General Adult Psychiatry)
por: Khattab, Elham, et al.
Publicado: (2022) -
Rubella immunity among pregnant women aged 15–44 years, Namibia, 2010()
por: Jonas, Anna, et al.
Publicado: (2016) -
Measles immunity among pregnant women aged 15–44 years in Namibia, 2008 and 2010
por: Cardemil, Cristina V., et al.
Publicado: (2016) -
Sodium valproate prescribing safety in women of childbearing potential
por: Donnelly, Shane, et al.
Publicado: (2021) -
Prevalence, trends, and characteristics of polypharmacy among US pregnant women aged 15 to 44 years: NHANES 1999 to 2016
por: Chang, Yu-Chien, et al.
Publicado: (2023)